Anti-cancer drug-combination composition comprising compound F-A

[0036] The therapeutic effect of embodiment 1 compound F-A on doxorubicin-induced cardiotoxicity

[0037] Rabbit test method for doxorubicin-induced cardiomyopathy (this experiment complies with relevant ethical regulations):

[0038] (1) Test with two sexes of rabbits whose initial body weight is 2.3 ± 0.2kg, group a is untreated animals (for control animals, n=8), group b is animals treated with doxorubicin (+ replace test substance with placebo, n=8), group c is doxorubicin and test substance treated animals (n=8), test substance is flavonoids F-A, F-B, F-C, respectively c1, c2 , Group c3.

[0039] (2) Groups b and c administered intravenously twice a week with doxorubicin, 1 mg / kg each time, for a total of 4 weeks, and group c took orally administered the test substance 20 mg / kg body weight per day, starting from the first day of doxorubicin treatment To start, feed the feed at the same time.

[0040] (3) After 4 weeks, separate the heart and weigh it, and detect the c

[0047] Therapeutic Effect of Example 2 Compound F-A on Doxorubicin-induced Cardiotoxicity

[0048] Inhibition of cardiomyocyte apoptosis in the H9c2 cardiotoxicity model:

[0049](1) After incubating H9c2 cells with different concentrations of flavonoids F-A, F-B, and F-C for 24 hours, the toxic effects of flavonoids on cardiomyocytes were evaluated by MTT colorimetry. H9c2 cells were incubated with flavonoids for 1 hour before adding 2.5 After cultured with μM DOX for 24 hours, MTT colorimetric method was used to screen the activity of flavonoids on doxorubicin (DOX)-induced cardiomyocyte apoptosis, and determine the optimal concentration range.

[0050] (2) After treating H9c2 cardiomyocytes with different seabuckthorn flavonoids for 1 hour, treat them with 2.5 μM DOX for 24 hours, then extract the protein, lyse, scrape, collect the cell lysate, centrifuge at 12000 g for 15 minutes, collect the supernatant and discard the precipitate, - Store at 80°C, and use BCA method to qua

[0057] Embodiment 3 contains the tablet of flavonoid compound

[0058] The following ingredients are produced for each tablet:

[0059]

[0060] The above-mentioned components were mixed according to the stated dosage, granulated, blended and compressed into tablets to prepare 250 mg tablets.